Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FCH and double SH3 domains protein 2 (FCHSD2) is a member of the F-BAR and double SH3-domain protein family, characterized by the presence of an N-terminal F-BAR domain and two SH3 domains[1][5]. FCHSD2 binds phosphatidylinositol phosphates, mediating its localization to membranes, and interacts with proline-rich partners such as WASP/N-WASP to stimulate actin polymerization via Arp2/3 complex activation[1][5]. In mouse cochlear hair cells, FCHSD2 regulates actin-rich structures important for auditory function[1]. It is also critically involved in clathrin-mediated endocytosis and the trafficking and recycling of receptor tyrosine kinases like EGFR in cancer cells; its loss alters receptor turnover, enhances cell proliferation and migration, and is associated with poor cancer prognosis[1]. FCHSD2 is further implicated in endosomal fission, with recruitment regulated by interactions with proteins like MICAL-L1 and intersectin-1[5]. Overall, while FCHSD2 has key adaptor and regulatory roles in membrane dynamics and cytoskeletal organization, it is not considered a classical therapeutic target such as a receptor, enzyme, or transporter[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FCH and double SH3 domains protein 2 (FCHSD2).